Younes, A. Et Al. 2017. Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. BLOOD , vol.130, no.Suppl_1 , 833.

Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, A. B., ... Nagler, A.(2017). Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. BLOOD , vol.130, no.Suppl_1, 833.

Younes, Anas Et Al. "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia," BLOOD , vol.130, no.Suppl_1, 833, 2017

Younes, Anas Et Al. "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia." BLOOD , vol.130, no.Suppl_1, pp.833, 2017

Younes, A. Et Al. (2017) . "Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia." BLOOD , vol.130, no.Suppl_1, p.833.

@article{article, author={Anas Younes Et Al. }, title={Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia}, journal={BLOOD}, year=2017, pages={833} }